1. Home
  2. TRS vs OGN Comparison

TRS vs OGN Comparison

Compare TRS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriMas Corporation

TRS

TriMas Corporation

HOLD

Current Price

$35.68

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$6.36

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRS
OGN
Founded
1986
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
TRS
OGN
Price
$35.68
$6.36
Analyst Decision
Strong Buy
Hold
Analyst Count
2
4
Target Price
$41.50
$11.75
AVG Volume (30 Days)
467.3K
3.1M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
0.45%
1.26%
EPS Growth
400.00
N/A
EPS
2.95
0.72
Revenue
$645,720,000.00
$6,216,000,000.00
Revenue This Year
$5.42
$0.42
Revenue Next Year
$4.27
$1.67
P/E Ratio
$12.10
$8.83
Revenue Growth
N/A
N/A
52 Week Low
$19.45
$5.69
52 Week High
$42.00
$13.28

Technical Indicators

Market Signals
Indicator
TRS
OGN
Relative Strength Index (RSI) 47.73 46.64
Support Level $35.17 $6.18
Resistance Level $37.20 $7.87
Average True Range (ATR) 1.01 0.26
MACD 0.03 0.06
Stochastic Oscillator 58.33 79.76

Price Performance

Historical Comparison
TRS
OGN

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Share on Social Networks: